Markets:

Overview

News

Currencies

International

Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

40.02 -0.02 (-0.04%)

Streaming Delayed Price Updated: 2:41 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CG Oncology, Inc. - Common stock

< Previous 1 2 Next >

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

3 Analysts Assess CG Oncology: What You Need To Know ↗

March 07, 2025

Via Benzinga

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

Why Cg Oncology Stock Rocketed 7% Higher Today ↗

October 08, 2025

One pundit believes this is a clinical-stage company well worth watching.

Via The Motley Fool

CG Oncology Stock Signals Bullish Momentum Ahead ↗

September 08, 2025

CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track...

Via Benzinga

Cg Oncology (CGON) Q2 Loss Widens 93% ↗

August 08, 2025

Via The Motley Fool

Which stocks are moving before the opening bell on Tuesday? ↗

July 22, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 22, 2025

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock ↗

July 16, 2025

Via Benzinga

Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗

May 04, 2025

Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?

Via Benzinga

Topics Artificial Intelligence

These stocks are moving in today's session ↗

April 28, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 28, 2025

Via Benzinga

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook ↗

April 28, 2025

Via Benzinga

Which stocks are gapping on Monday? ↗

April 28, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why ↗

April 28, 2025

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025.

Via Benzinga

These stocks are moving in today's pre-market session ↗

April 28, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗

April 28, 2025

Via Benzinga

CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug ↗

April 28, 2025

The companies are working on treatments for a form of bladder cancer.

Via Investor's Business Daily

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings ↗

April 28, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 28, 2025

Via Benzinga

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

April 16, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

April 11, 2025

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts ↗

March 25, 2025

Via Benzinga

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗

March 06, 2025

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.